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Abstract
Actinic keratoses (AK) are common precancerous lesions of the skin. Numerous interventions exist for the treatment of
AK, including lesion- and field-directed approaches. In daily practice, different treatment modalities are often combined
to maximize clearance rates. However, whether a combination therapy is preferable to monotherapy in terms of efficacy
and safety has been subject of intense debate. In this review, we summarize the current knowledge on the efficacy and
safety of local combination therapies for the treatment of patients with AK. Combination approaches of cryosurgery fol-
lowed by photodynamic therapy (PDT), laser-assisted PDT, PDT in combination with topical interventions and micro-
needling-assisted PDT have shown slightly better efficacy results with similar tolerability compared to the respective
monotherapy. However, the individual usage of combination therapies should be checked on a case-by-case basis and
take into account individual patient- and lesion-specific aspects as more resources are needed and because the individ-
ual monotherapies are already highly effective.
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Introduction
Long-term exposure to ultraviolet (UV) radiation can lead to
the formation of actinic keratoses (AK) in light-skinned individ-
uals.1,2 These precancerous lesions present as diffuse red and
keratotic or scaling plaques with a rough, sand paper-like surface
on chronically sun-exposed areas such as the face, ears, arms and
dorsal hands.2,3 Visible AK lesions are often surrounded by tis-
sue that harbours significant UV-induced histologic and genetic
alterations but appears clinically unaltered. This so-called field
cancerization is a commonly observed phenomenon in chroni-
cally sun-damaged skin and requires appropriate treatment
approaches.4 Although the risk is presumably low for single
lesions, AK can progress to cutaneous squamous cell carcinoma
(cSCC).5 The presence of multiple lesions and additional signs
of chronic UV damage on the adjacent skin increases the risk for
progression considerably.6,7 As it is currently not possible to pre-
dict which AK will transform into invasive cSCC, early and con-
sequent treatment of AK lesions is recommended by
international treatment guidelines.8
Today, a variety of interventions is available for the effective
treatment of AK. Selecting an appropriate therapy may pose a
major challenge in daily practice. According to the mode of
application, interventions are traditionally classified as either
lesion- or field-directed.9 Lesion-based approaches are suited for
single or isolated AK, whereas field-directed treatments are
preferable for multiple AK as they also address subclinical
changes of an actinically damaged field. Both strategies can be
combined for difficult-to-treat AK such as hyperkeratotic lesions
or lesions on the dorsal hands. Common examples for the com-
bination of a lesion-directed with a field-directed regimen are
surgery or cryosurgery followed by a topical intervention or
laser-assisted photodynamic therapy (PDT). However, ablative
and non-ablative lasers may also be applied as field-directed
modalities. Examples for the combination of two field-directed
approaches include microneedling (MN)-assisted PDT and PDT
followed by a topical intervention such as imiquimod, 5-fluor-
ouracil (5-FU) or ingenol mebutate or the sequential treatment
with PDT.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2020, 34, 727–732
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
DOI: 10.1111/jdv.15998 JEADV
Combination therapies are commonly applied in the daily
practice; however, it has been subject of debate if combination
therapies should be preferred to monotherapies for the treat-
ment of AK, as monotherapies already offer high clearance rates.
In this narrative review, we aimed to summarize the current
knowledge on the efficacy and safety of clinically relevant combi-
nation therapies for the treatment of patients with AK in order
to provide a practical aid for clinical decision-making.
Combination of lesion- and field-directed
regimens
Cryosurgery and topical interventions
Cryosurgery is a practicable, widely used and presumably lesion-
directed approach for isolated lesions. During the procedure, liq-
uid nitrogen is applied in one to three freeze–thaw cycles in
order to destroy AK lesions. In patients with multiple lesions or
field cancerization, cryosurgery can also be applied over a wider
area as ‘cryopeeling’ (extensive cryosurgery), underlining that
the mode of application but not the intervention per se determi-
nes whether a treatment is lesion-directed or field-directed.10
Cryosurgery is highly recommended for single AK in pertinent
treatment guidelines. However, in daily practice, isolated lesions
without signs of actinic damage are rarely observed and the
addition of a field-directed treatment can help to overcome the
limitations of cryosurgery. A variety of topical agents for the
treatment of AK is available with distinct mechanisms of actions,
ranging from cytostatic effects to immune activation. The down-
sides are a longer duration of application and questionable effi-
cacy in patients with thicker lesions who were commonly
excluded in larger trials. This may be due to a poorer penetra-
tion of topical drugs through hyperkeratotic lesions. In contrast,
cryosurgery showed high clearance rates, particularly in thicker
AK which provides a solid rationale to combine this approach
with field-directed drug treatment.11
We recently investigated in a systematic review and meta-ana-
lysis whether an upfront combination of cryosurgery with a topi-
cal intervention is superior to cryosurgery alone.12 We identified
nine randomized controlled trials (RCTs) with an overall sample
size of n = 1644 participants. The majority investigated cryosur-
gery followed by imiquimod (n = 4). Two studies assessed cryo-
surgery followed by ingenol mebutate and the remaining three
studies assessed 3% diclofenac in 2.5% hyaluronic acid, 5-FU
0.5% cream and photodynamic therapy with 5-aminolevulinic
acid (5-ALA) after cryosurgery, respectively. The pooled results
showed significantly higher participant complete clearance rates
for cryosurgery in combination with a topical approach com-
pared to monotherapy (RR 1.74, 95% CI 1.25–2.43. I² = 73%).
However, the quality of evidence for this result was estimated as
low (GRADE ++‐‐). This rating indicates that we have limited
confidence in the effect estimate. The true effect may be substan-
tially different from the estimate of the effect.13 Besides, the
proportion of patients who had at least 75% of their lesions
cleared was not statistically different between the combination
and monotherapy group (RR 1.64, 95% CI 0.88–3.03, I² = 77%,
quality of evidence: very low, GRADE +‐‐‐). Hence, we have
very little confidence in the effect estimate: The true effect is
likely to be substantially different from the estimate of effect.13
Safety was defined as the number of patients who completed the
study protocol and did not withdraw due to adverse events. The
proportion was equally distributed in both groups (RR 0.98, 95%
CI 0.95–1.01, I² = 75%, GRADE +‐‐‐). The evidence for this
outcome was graded to be very low GRADE +‐‐‐. We also con-
ducted comparator-specific stratified analysis for the interventions
imiquimod and ingenol mebutate. Cryosurgery followed by inge-
nol mebutate showed no significant differences regarding partici-
pant complete clearance rate (RR 3.51, 95% CI 0.22–56.53,
I² = 77%, GRADE +‐‐‐) or partial clearance rate (RR 2.97, 95%
CI 0.28–30.96, I² = 83%, GRADE +‐‐‐) in comparison with
cryosurgery alone. The combination of cryosurgery with imiqui-
mod revealed no significant difference of participant complete
clearance in comparison with cryosurgery alone (RR 2.46, 95%
CI 0.63–9.57, I² = 87%, GRADE +‐‐‐). In all studies, cryosur-
gery was performed upfront. In order to decrease the targeted area
and thereby minimize commonly observed adverse effects such
as hypopigmentation, starting with a topical drug treatment and
subsequently performing cryosurgery for recalcitrant lesion may
be another interesting approach which has not yet been evaluated
in RCTs to our knowledge. The interpretation of the data avail-
able for cryosurgery plus topical treatment is difficult. While for
the pooled analysis, a statistically significant superiority for the
combination was observed, this difference was not consistent in
the comparator-stratified specific analyses. This may be due to a
small sample size for the specific comparators but can also indi-
cate that the advantage for the combination does not exist for
specific agents. Furthermore, there was high clinical and statisti-
cal heterogeneity which needs to be kept in mind in the interpre-
tation of the pooled analysis. Nevertheless, based on these results
and our clinical experience, we still propose a small advantage
for the combination therapy, in particular if multiple lesions or
field-cancerization are present.
Laser-assisted photodynamic therapy
Photodynamic therapy with 5-ALA or its ester methyl-aminole-
vulinate (MAL) is a highly effective treatment for multiple AK
or field cancerization with an excellent cosmetic outcome.14,15
Both photosensitizers penetrate the stratum corneum and selec-
tively accumulate in dysplastic cells where they are converted to
the photosensitizer protoporphyrin IX (PpIX).16,17 However,
one of the main side effects is local pain during illumination,
which can limit treatment compliance and patient satisfaction.18
Other limiting factors include the thickness of the individual
lesions, as the photosensitizing agent poorly penetrates hyperk-
eratotic lesions, therefore requiring curettage or another physical
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pretreatment prior to PDT. As field-directed approach, PDT
may be combined with lesion-targeted pretreatment by ablative
and non-ablative laser devices (Fig. 1). Ablative fractional lasers
including Erbium:YAG or carbon dioxide (CO2) lasers heat the
treated tissue up to 100°C and thereby vaporize microscopic ver-
tical channels into the skin that facilitate the penetration and
enrichment of 5-ALA or MAL in dysplastic cells.19 This concept
has been denoted as laser-assisted drug delivery.19 We recently
performed a meta-analysis including seven RCTs which demon-
strated that laser-assisted PDT is more efficient but not more
painful than PDT or laser monotherapy for the treatment of
patients with AK.20 Six of the seven studies assessed MAL and
one study 5-ALA as photosensitizer. Regarding the type of laser,
three studies investigating an Erbium:YAG laser were included,
whereas four studies assessed a carbon dioxide (CO2) laser.
However, the results of the meta-analysis were pooled irrespec-
tive of the individual photosensitizer or laser and therefore
assumptions regarding the influence of the photosensitizer or
the type of laser cannot be made. The clearance rates for laser-
assisted PDT were significantly higher for the combination than
for PDT monotherapy (RR 1.33, 95% CI 1.24–1.42, I² = 25%);
however, the evidence for this outcome was graded as low
(GRADE ++‐‐). Besides, no difference in pain intensity between
laser-assisted PDT and other interventions was observed (mean
difference 0.31, 95% CI 0.12 to +0.74, I² = 0%, low quality of
evidence, GRADE ++‐‐).
In addition to the evidence presented here, the experience of
the practitioner’s individual experience regarding specific com-
binations must also be taken into account. The enrichment of
PpIX in PDT was investigated comparatively after several physi-
cal pretreatments in an intra-individual trial.21 It was highest
with ablative fractional laser, followed by microdermabrasion,
microneedling and curettage. However, the photosensitizer
uptake does not necessarily reflect the effectiveness of PDT.
Based on these results, the clinical efficacy of PDT was further
evaluated after a tailored pretreatment with either ablative frac-
tional laser (AFL) or microdermabrasion in a recent side-by-side
trial.22 Two large areas were randomized intra-individually to
receive a single treatment with AFL + daylight PDT or
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Figure 2 Network of combination therapies for actinic keratoses. 5-FU, 5-fluorouracil; ALA, aminolevulinic acid; CO2, carbon dioxide;
MAL, methyl aminolevulinate; PDT, photodynamic therapy.
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microdermabrasion + daylight PDT. Interestingly, AFL was
superior to microdermabrasion in terms of lesion clearance, but
was also associated with a higher rate of local skin reactions.
Surgical procedures and topical interventions
Shave excision and complete excision Shave excision or com-
plete excision as excisional biopsy in combination with topical
interventions is clinically widely used for AK. They are either
applied to remove hyperkeratotic AK in order to improve the
permeation capability of topical drugs or to remove single
lesions that were not cleared by previous topical therapies. How-
ever, high-quality evidence is lacking as no RCTs and only few
case series have been published on shave and complete excision
for AK.23-25
Curettage Another question in this context is whether curet-
tage of lesions can be considered as true surgical treatment. In
many cases, curettage is performed on hyperkeratotic lesions
prior to PDT to improve the penetration of the photosensitizers
and to remove crusts or keratotic components. Therefore, it is
certainly correct to classify curettage prior to a treatment as a
basic measure instead of speaking of sequential combination
therapy. Physical pretreatment is currently recommended as
standard measure in international PDT protocols.26 In a ran-
domized, intra-individual study (n = 22), Nissen et al.23 investi-
gated whether PpIX accumulation in AK lesions can be
increased by different interventions in order to improve MAL-
PDT efficacy on extremities. Four symmetrical areas on dorsal
hands were selected for pretreatment with or without curettage
and MAL application for either 3 h or 21 h prior to illumina-
tion. Extended MAL application for 21 h led to an increased
accumulation of PpIX in the treated lesions, but did not result in
better treatment outcomes. MAL application for 3 h without
previous curettage achieved the lowest median total clearance
rate (33.3%) due to insufficient PpIX accumulation, whereas
all other interventions showed improved clearance rates
(curettage + 3 h MAL and no curettage + 21 h MAL 55.0%,
curettage + 21 h MAL 53.6%, statistically not significant).
Additionally, PpIX accumulation was correlated with pain and
erythema. These results indicate that PpIX accumulation in AK
lesions on dorsal hands can be increased by curettage and/or
extended MAL application prior to illumination but can also
result in enhanced side effects and does not improve clearance
rates. In another case series, Jambusaria-Pahlajani et al.24 inves-
tigated the efficacy of curettage prior to PDT in four organ
transplant recipients with multiple AK refractory to other treat-
ments. Hyperkeratotic lesions were removed by light curettage,
followed by a topical treatment with 5-FU 5% cream twice daily
for 5 days and PDT (MAL-PDT: n = 1, ALA-PDT: n = 3). All
patients had a complete or partial clearance of their AK and
good cosmetic outcome, indicating that this sequential approach
is effective. Gholam et al. retrospectively compared the efficacy
of pretreatment of MAL-PDT with either curettage (n = 15), sal-
icylic acid 10% (n = 15) or urea cream 40% (n = 14).25 The
combination with curettage achieved the highest response rates
(68.5%), followed by salicylic acid (61.4%) and urea cream
(60.8%), albeit without statistical significance. Patients pre-
treated with curettage experienced significantly less pain on a
visual analogue scale than salicylic acid and urea-pretreated
patients (curettage: 4.4  2.1 vs. salicylic acid: 6.3  2.7,
P = 0.02; urea: 6.1  1.8, P = 0.04) and had less pronounced
local reactions compared to the other interventions. The
patients’ satisfaction and the cosmetic outcome evaluated four
weeks after PDT were good to excellent with no significant dif-
ferences between the groups.
Combination of field-directed regimens
Topical interventions combined with PDT
The combination of two or more field-directed treatments is less
established than the combination of lesion- and field-directed
regimens (Fig. 2). As a fixed combination of 5-FU 0.5% and
10% salicylic acid is available on the market, we did not consider
this agent as sequential combination for the purpose of our
review, although both topical field-directed regimens may also
be applied as monotherapy. A sequential combination of two
field-directed treatments may offer additive effects through dif-
ferent mechanisms of action. The results of a meta-analysis con-
firm this hypothesis and suggest that the combination of PDT
with another topical drug intervention does improve AK clear-
ance rates compared to either monotherapy alone.27 Ten RCTs
with an overall sample size of 277 participants were included.
Four of these studies investigated a combination of PDT with
imiquimod cream, three with 5-FU cream and one each with
ingenol mebutate gel, tazarotene gel and calcipotriol ointment,
respectively. The results showed that patients treated with a
combination of PDT and a topical intervention showed higher
participant complete (RR 1.63; 95% CI 1.15–2.33, I² = 3%) and
partial clearance rates (RR 1.19; 95% CI 0.84–1.67, I² = 38%).
However, the quality of evidence for these outcomes ranged
from low (GRADE ++‐‐) to very low (GRADE ++‐‐) according
to the authors judgement with the GRADE approach. Similarly,
the lesion-specific clearance was higher for PDT plus topical
intervention compared to monotherapy, though the certainty of
the evidence was estimated as very low (RR 1.48; 95% CI 1.04–
2.11, I² = 93%, GRADE ++‐‐). The authors reported that PDT-
induced pain and local skin reactions after treatment were
poorly and inconsistently described in the identified RCTs.
Hence, a general assumption about the effect of adding a topical
intervention to PDT treatment cannot be made. To investigate
the influence of the topical intervention, a subgroup analysis was
performed for PDT combined with imiquimod. This analysis
revealed an increased participant complete clearance rate
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compared to monotherapy (RR 1.57, 95% CI 1.09–2.25,
I² = 0%, GRADE +‐‐‐). However, the significance of this effect
remains questionable as the lower limit of the 95% confidence
interval is close to the line of no effect. This meta-analysis high-
lights that the sequential application of two field-directed treat-
ments can represent a suitable approach in patients with
multiple AK and field cancerization; however, the true efficacy
of this combination may deviate and depend on the clinical con-
text.
Microneedling-assisted PDT
Pretreatment with microneedling (MN) represents another
approach to augment the effects of PDT and topical drugs. MN
can be achieved by a series of tiny needles either on a roller or a
mechanical stamp which puncture the superficial epidermis in
order to enhance drug delivery for an improved PDT efficacy.
The combination of microneedling with PDT was initially devel-
oped to decrease the incubation time of the photosensitizer and
to increase the efficacy of PDT by enhanced drug delivery
through the perforated microchannels.
Thus, several RCTs investigated microneedling-assisted PDT
vs. PDT monotherapy. Torezan et al.28 compared the efficacy
of two MAL-PDT approaches in a randomized, split-face study
(n = 10). AK were pretreated with curettage on one side, and
MN was conducted after MAL application on the other side of
the face. Patients were illuminated with a red light-emitting
diode afterwards for 90 min. Both interventions led to
improved cosmetic outcomes and a clearance rate of 88.3%
with no significant differences. However, adverse effects as ery-
thema, oedema, crusting and pain were more severe and more
commonly reported on the MN-treated side. Another study by
Spencer et al. investigated whether MN and subsequent ALA-
PDT is more efficacious than ALA-PDT monotherapy for clear-
ing AK located on the face of 20 patients.29 MN pretreatment
led to a significantly better mean AK lesion reduction than
PDT monotherapy (89.3% vs. 69.5%). Besides, 75% of the pre-
treated sides achieved complete clearance in comparison with
30% of the monotherapy side. The Microneedle Photodynamic
Therapy II (MNPDT-II) study had a randomized, single-
blinded, split-face controlled, 2 9 2 factorial study design
(n = 33).30 Participants were randomized to receive either 5-
ALA application for 10 min or 20 min prior to illumination
after a pretreatment with a microneedle roller or a sham roller.
For the 20-min incubation arm, a statistically significantly dif-
ferent average AK clearance of 76% was achieved on the MN
side vs. 58% on the sham side, including three patients with
complete clearance. However, the latter result was not statisti-
cally significant. Pain during illumination was not significantly
different between both pretreatment groups. MAL incubation
for 10 min resulted in lower AK clearance rates of 43% after
MN pretreatment and 38% on the sham side with no signifi-
cant difference. Pain during illumination was also not
significantly different between MN and sham pretreatment.
Lev-Tov et al.31 undertook a trial with 51 participants in which
MN and sham pretreatments were randomized to the right and
left foreheads and the sham-treated sides were incubated with
5-ALA for 60 min. Subsequently, MN-pretreated sides were
further randomized to 20, 40 or 60 min 5-ALA incubation. The
lesion response rate for the 20, 40 and 60 min MN incubation
times vs. the corresponding sham MN treatment with 60 min
5-ALA incubation were 71.4% and 68.3%, 81.1% and 79.9%,
and 72.1% and 74.2%, respectively. The differences in efficacy
between the MN and sham pretreatments were not significant.
Statistical significant differences in pain scores between MN
and sham pretreatment were reported, but these were relatively
low. No adverse events were reported. Besides this, unpublished
results were available for a registered phase-2 trial
(NCT02632110) comparing the effect of MN, incubation time
and light power density on ALA-PDT for the field treatment of
AK on the face among 137 participants.32 MN pretreatment
resulted in a better mean lesion clearance as well as participant
complete clearance than ALA-PDT monotherapy.
Overall, the studies described here suggest that MN pretreat-
ment may enhance the efficacy of PDT, although the data from
these RCTs are heterogeneous. The study by Torezan et al.
reported more adverse events with the combination and the
microneedling pretreatment itself can cause painful sensations
apart from the illumination which was not consistently reported.
Nevertheless, this combination can be beneficial for therapy-
resistant or difficult-to-treat lesions. However, the procedure of
the MN needs to be standardized for the use in daily practice.
Concluding remarks
As already a variety of effective lesion- and field-directed proce-
dures exist, sequential combinations further increase the number
of possible approaches. Large clinical heterogeneity results from
differences in timing and the type of application, which are not
standardized particularly for physical or ablative therapies such
as cryosurgery, curettage or laser application. Also, it is currently
difficult to assess which treatment combination is the most effec-
tive. Interestingly, the majority of studies investigating combina-
tion therapies covered combination therapies with PDT, which
does not necessarily mean that PDT is the best option for a com-
bination treatment. As we did not perform a systematic litera-
ture search for the identification of studies, we cannot exclude
that the combination approaches presented here are biased by
our own clinical experience.
Overall, the results on both the individual study and the
meta-analysis level allow the interpretation that a small increase
in effectiveness can be achieved through a combination of sev-
eral therapy procedures. The tolerability seems to be similarly
good, and the occurrence of side effects is not massively
increased. Especially, a combination of lesion-directed and field-
directed approaches might be particularly helpful for
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hyperkeratotic AK in order to improve permeation of the topical
intervention. However, we consider the strength of the addi-
tional effect of a combination therapy to be rather low. This is
probably due to the fact that most interventions as monothera-
pies have a good effectiveness with a high rate of lesion clear-
ance. Especially for lesions that are not pretreated, monotherapy
is widely sufficient for disease control. Here, a primary combina-
tion of several procedures may represent overtreatment and
waste resources of the healthcare system.
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